Efficacy and Safety of Different Conbercept Injection Regimens in the Treatment of Choroidal Neovascularization in Pathological Myopia: a Retrospective Study

Overview

Journal Int Ophthalmol

Specialty Ophthalmology

Date 2023 Jul 31

PMID 37523104

Authors

Bin Gong

Yuxia Bo

Peng Zhang

Jing Wang

Lei Gao

Affiliations

Soon will be listed here.

Abstract

Purpose: To investigate the clinical efficacy of conbercept 1 + pro re nata (PRN) (i.e., reinjection as needed after one injection) and 3 + PRN (reinjection as needed after 3 months of injection) regimens in choroidal neovascularization secondary to pathological myopia (PM-CNV).

Methods: From 06/2019 to 06/2020, 65 patients (65 eyes) confirmed with PM-CNV were included in this retrospective study. Intravitreal injection of 0.5 mg conbercept was conducted either with the 1 + PRN or 3 + PRN strategy. Patients were followed up for 12 months. The best-corrected visual acuity (BCVA), central retinal thickness (CRT), CNV lesion leakage area, the number of injections, and postoperative adverse reactions were observed.

Results: The mean age of the patients was 42.10 ± 4.69 years, and the average diopter was - 11.26 ± 2.97D. The BCVA at month 3 in the 3 + PRN (n = 30) group was lower than in the 1 + PRN (n = 35) group (P < 0.001). The CRT at month 3 in the 3 + PRN group was lower than in the 1 + PRN group (P < 0.001). After 12 months, there were no differences in the BCVA and CRT between the two groups (P > 0.05). The number of injections was less in 1 + PRN than in 3 + PRN (2.14 ± 1.06 vs. 3.37 ± 0.76, P < 0.001) at 12 months. No serious treatment-related ocular complications or serious systemic adverse events were found.

Conclusion: The 1 + PRN and 3 + PRN strategies of intravitreal injection of conbercept are effective in treating PM-CNV. The 1 + PRN regimen required fewer injections, and it might be more suitable for the treatment of PM-CNV.

References

Ohno-Matsui K, Kawasaki R, Jonas J, Cheung C, Saw S, Verhoeven V . International photographic classification and grading system for myopic maculopathy. Am J Ophthalmol. 2015; 159(5):877-83.e7. DOI: 10.1016/j.ajo.2015.01.022. View

Williams K, Bertelsen G, Cumberland P, Wolfram C, Verhoeven V, Anastasopoulos E . Increasing Prevalence of Myopia in Europe and the Impact of Education. Ophthalmology. 2015; 122(7):1489-97. PMC: 4504030. DOI: 10.1016/j.ophtha.2015.03.018. View

Yoshida T, Ohno-Matsui K, Yasuzumi K, Kojima A, Shimada N, Futagami S . Myopic choroidal neovascularization: a 10-year follow-up. Ophthalmology. 2003; 110(7):1297-305. DOI: 10.1016/S0161-6420(03)00461-5. View

Ohno-Matsui K, Yoshida T, Futagami S, Yasuzumi K, Shimada N, Kojima A . Patchy atrophy and lacquer cracks predispose to the development of choroidal neovascularisation in pathological myopia. Br J Ophthalmol. 2003; 87(5):570-3. PMC: 1771643. DOI: 10.1136/bjo.87.5.570. View

Tong J, Chan W, Liu D, Lai T, Choy K, Pang C . Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization. Am J Ophthalmol. 2006; 141(3):456-62. DOI: 10.1016/j.ajo.2005.10.012. View

Kasahara K, Moriyama M, Morohoshi K, Yoshida T, Simada N, Nagaoka N . SIX-YEAR OUTCOMES OF INTRAVITREAL BEVACIZUMAB FOR CHOROIDAL NEOVASCULARIZATION IN PATIENTS WITH PATHOLOGIC MYOPIA. Retina. 2016; 37(6):1055-1064. DOI: 10.1097/IAE.0000000000001313. View

Tufail A, Patel P, Sivaprasad S, Amoaku W, Browning A, Cole M . Ranibizumab for the treatment of choroidal neovascularisation secondary to pathological myopia: interim analysis of the REPAIR study. Eye (Lond). 2013; 27(6):709-15. PMC: 3682373. DOI: 10.1038/eye.2013.8. View

Cheung C, Arnold J, Holz F, Park K, Lai T, Larsen M . Myopic Choroidal Neovascularization: Review, Guidance, and Consensus Statement on Management. Ophthalmology. 2017; 124(11):1690-1711. DOI: 10.1016/j.ophtha.2017.04.028. View

Wang E, Chen Y . Intravitreal anti-vascular endothelial growth factor for choroidal neovascularization secondary to pathologic myopia: systematic review and meta-analysis. Retina. 2013; 33(7):1375-92. DOI: 10.1097/IAE.0b013e31827d260a. View

10.

Calvo-Gonzalez C, Reche-Frutos J, Fernandez-Vigo J, Saenz-Frances F, Fernandez-Perez C, Garcia-Feijoo J . Long-Term Outcomes of Two Different Initial Dosing Regimens of Intravitreal Ranibizumab Used to Treat Myopic Choroidal Neovascularization. Ophthalmologica. 2017; 238(4):196-204. DOI: 10.1159/000478030. View

11.

Kung Y, Wu T, Huang Y . One-year outcome of two different initial dosing regimens of intravitreal ranibizumab for myopic choroidal neovascularization. Acta Ophthalmol. 2014; 92(8):e615-20. DOI: 10.1111/aos.12457. View

12.

Ikuno Y, Ohno-Matsui K, Wong T, Korobelnik J, Vitti R, Li T . Intravitreal Aflibercept Injection in Patients with Myopic Choroidal Neovascularization: The MYRROR Study. Ophthalmology. 2015; 122(6):1220-7. DOI: 10.1016/j.ophtha.2015.01.025. View

13.

Zhang M, Yu D, Yang C, Xia Q, Li W, Liu B . The pharmacology study of a new recombinant human VEGF receptor-fc fusion protein on experimental choroidal neovascularization. Pharm Res. 2008; 26(1):204-10. DOI: 10.1007/s11095-008-9718-9. View

14.

Li X, Xu G, Wang Y, Xu X, Liu X, Tang S . Safety and efficacy of conbercept in neovascular age-related macular degeneration: results from a 12-month randomized phase 2 study: AURORA study. Ophthalmology. 2014; 121(9):1740-7. DOI: 10.1016/j.ophtha.2014.03.026. View

15.

Zafar S, Staggers K, Gao J, Liu Y, Patel P, Foster P . Evaluation of retinal nerve fibre layer thickness as a possible measure of diabetic retinal neurodegeneration in the EPIC-Norfolk Eye Study. Br J Ophthalmol. 2021; 107(5):705-711. PMC: 9460960. DOI: 10.1136/bjophthalmol-2021-319853. View

16.

Yan M, Huang Z, Lian H, Song Y, Chen X . Conbercept for treatment of choroidal neovascularization secondary to pathologic myopia. Acta Ophthalmol. 2018; 97(5):e813-e814. DOI: 10.1111/aos.13632. View

17.

Nie X, Wang Y, Yi H, Qiao Y . Intravitreal conbercept for choroidal neovascularisation secondary to pathological myopia in a real-world setting in China : Intravitreal conbercept was safe and effective in treating myopic choroidal neovascularization. BMC Ophthalmol. 2021; 21(1):116. PMC: 7934258. DOI: 10.1186/s12886-021-01877-8. View

18.

Keane P, Liakopoulos S, Chang K, Heussen F, Ongchin S, Walsh A . Comparison of the optical coherence tomographic features of choroidal neovascular membranes in pathological myopia versus age-related macular degeneration, using quantitative subanalysis. Br J Ophthalmol. 2008; 92(8):1081-5. PMC: 2749310. DOI: 10.1136/bjo.2008.138891. View

19.

Maloney M, Payne S, Herrin J, Sangaralingham L, Shah N, Barkmeier A . Risk of Systemic Adverse Events after Intravitreal Bevacizumab, Ranibizumab, and Aflibercept in Routine Clinical Practice. Ophthalmology. 2020; 128(3):417-424. DOI: 10.1016/j.ophtha.2020.07.062. View

20.

Cho H, Yoo S, Kim H, Kim J, Kim C, Lee T . Risk factors for geographic atrophy after intravitreal ranibizumab injections for retinal angiomatous proliferation. Am J Ophthalmol. 2014; 159(2):285-92.e1. DOI: 10.1016/j.ajo.2014.10.035. View